|
|
Article: Ambrx Licenses HGH Program To Merck Serono.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
While wrapping up a Phase I/II trial with ARX201, Ambrx Inc. exclusively licensed the pegylated recombinant human growth hormone (HGH) to Merck Serono SA.
Kevin Eastwood, vice president of corporate development at Ambrx, said the deal was "built around ARX201" but also includes the use of Ambrx's proprietary ReCODE pegylation technology to create backup molecules in the HGH space.
In exchange for worldwide development and commercialization rights to ARX201 and the rest of the HGH program, Geneva-based Merck Serono will pay San Diego-based Ambrx an undisclosed up-front fee as well as potential clinical, regulatory and commercial ...